When to Suspect Acquired Hemophilia in Non-Hypertensive Intracerebral Hemorrhage
Suspect acquired hemophilia A (AHA) in any patient with spontaneous intracerebral hemorrhage (ICH) who has no prior bleeding history and presents with an isolated prolonged aPTT, particularly in elderly patients. 1
Key Clinical Triggers for Suspicion
Primary Red Flags
- Spontaneous ICH without hypertension in a patient with no previous bleeding history 2, 3
- Isolated prolonged activated partial thromboplastin time (aPTT) on initial coagulation screening 1
- Elderly age (median age ~66.5 years in ICH cases) 2
- Post-partum women presenting with spontaneous bleeding 1
Hemorrhage Patterns Suggesting AHA
The evidence shows specific ICH patterns in AHA patients 2:
- Intracerebral hemorrhage (50% of cases)
- Acute subdural hematoma (38%)
- Subarachnoid hemorrhage (12%)
- Intraventricular hemorrhage (19%)
- Multiple simultaneous hemorrhage types (occurred in 3 patients, highly suspicious)
Critical Laboratory Finding
An unexplained isolated prolonged aPTT is the hallmark diagnostic clue 1. The mean aPTT in reported ICH cases was 76.0 ± 28.6 seconds with markedly reduced factor VIII activity 2.
Algorithmic Approach to Suspicion
Step 1: Initial Presentation Assessment
Suspect AHA if the patient has:
- Spontaneous ICH without typical risk factors (no hypertension, no trauma, no anticoagulation)
- AND no personal or family history of bleeding disorders 4
- AND elderly age or post-partum status
Step 2: Laboratory Screening
Order immediate coagulation studies:
- If aPTT is prolonged but PT/INR is normal → high suspicion for AHA
- Proceed immediately to mixing study
- If mixing study fails to correct → strongly suggests inhibitor presence 1, 3
Step 3: Confirmatory Testing
- Measure factor VIII activity (expect <5% in severe cases) 5
- Quantify factor VIII inhibitor using Bethesda assay 1
- Rule out lupus anticoagulant (can transiently coexist but doesn't exclude AHA) 5
Common Pitfalls to Avoid
Pitfall #1: Assuming Normal Prior Coagulation Status Excludes AHA
Critical caveat: AHA can develop acutely between surgeries or procedures 6. A 58-year-old patient had normal coagulation 30 years prior but developed massive ICH post-cranioplasty due to newly acquired hemophilia. Always recheck coagulation studies before each neurosurgical procedure, regardless of prior normal results.
Pitfall #2: Delaying Investigation of Isolated Prolonged aPTT
Even without active bleeding, an isolated prolonged aPTT warrants immediate investigation 1. Not all AHA patients present with significant bleeding initially, but ICH can develop rapidly.
Pitfall #3: Attributing ICH to Hypertension Alone
In the absence of hypertension, do not assume typical hypertensive ICH. The combination of non-hypertensive status + spontaneous ICH + no trauma history should trigger coagulation workup 2, 3.
Pitfall #4: Missing Recurrent Ipsilateral Hemorrhage
Recurrent bleeding in the same location after initial treatment suggests either inadequate hemostatic control or an underlying structural lesion 2, 3, 7. The evidence shows rebleeding occurred in multiple cases, including one fatal case 8 hours post-evacuation 3.
Clinical Context and Nuances
The international guidelines emphasize that bleeding phenotype rarely correlates with laboratory assessments in AHA 1. This means you cannot rely on inhibitor titer or factor VIII levels to predict ICH risk—clinical suspicion based on presentation pattern is paramount.
Mortality is substantial: Overall survival in AHA-associated ICH is only 62%, with just 30% of survivors achieving full neurological recovery 2. This high morbidity and mortality underscores the critical importance of early recognition.
The evidence shows that surgical intervention occurred in only 31% of ICH cases 2, likely because hemostatic control must be achieved first. One case demonstrated fatal rebleeding after hematoma evacuation when AHA was not recognized preoperatively 3.
Immediate Action When AHA is Suspected
Once suspected based on clinical presentation and isolated prolonged aPTT:
- Do not delay factor VIII activity and inhibitor testing
- Consult hematology immediately for hemostatic management 1
- Initiate bypassing agents (recombinant activated factor VIIa or activated prothrombin complex concentrate) if active bleeding 1
- Avoid surgical intervention until hemostatic control is achieved, unless life-threatening mass effect 2, 3
- Begin immunosuppressive therapy immediately after diagnosis confirmation 1
The evidence demonstrates that early recognition and prompt initiation of bypassing agents may improve outcomes in this highly morbid condition 2.